Page last updated: 2024-08-23

bezafibrate and Myocardial Infarction

bezafibrate has been researched along with Myocardial Infarction in 38 studies

Research

Studies (38)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	14 (36.84)	18.2507
2000's	21 (55.26)	29.6817
2010's	3 (7.89)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D	1
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S	1
Behar, S; Benderly, M; Boyko, V; Goldenberg, I; Sidi, R; Tanne, D; Tenenbaum, A	1
Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldberg, I; Inoue, T; Matas, Z; Node, K; Schwammenthal, E; Tenenbaum, A	1
Behar, S; Boyko, V; Goldenberg, I; Guetta, V; Tanne, D; Tennenbaum, A	1
Behar, S; Boyko, V; Brodov, Y; Chouraqui, P	1
Behar, S; Boyko, V; Fisman, EZ; Leor, J; Mandelzweig, L; Motro, M; Tenenbaum, A	1
Arcavi, L; Behar, S; Boyko, V; Caspi, A; Knobler, H; Reshef, N	1
Battler, A; Behar, S; Boyko, V; Goldbourt, U; Haim, M	1
Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A	1
Behar, S; Boyko, V; Fisman, EZ; Motro, M; Tanne, D; Tenenbaum, A	1
Fisman, EZ; Motro, M; Tenenbaum, A	1
Loewen, P; McCormack, J	1
Behar, S; Boyko, V; Goldbourt, U; Goldenberg, I; Reicher-Reiss, H	1
Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R	1
Behar, S; Boyko, V; Brunner, D; Doolman, R; Goldbourt, U; Haim, M; Sela, BA; Tanne, D	1
Miller, M	1
Battler, A; Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R	1
Benderly, M; Goldbourt, U; Goldenberg, I	1
de Faire, U; Ericsson, CG; Hamsten, A; Nilsson, J	1
Barasch, E; Behar, S; Benderly, M; Caspi, A; Goldbourt, U; Graff, E; Pelled, B; Reicher-Reiss, H; Reisin, L; Roguin, N	1
Agmon, J; Behar, S; Caspi, A; Goldbourt, U; Graff, E; Kaplinsky, E; Kishon, Y; Mandelzweig, L; Reicher-Reiss, H; Weisbort, J	1
de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B	1
Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H; Shotan, A	1
Barradell, LB; Goa, KL; Plosker, GL	1
Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P	1
Ector, H	1
Kesäniemi, YA	1
Ericsson, CG	1
Behar, S; Brunner, D; Goldbourt, U; Reicher-Reiss, H	1
Behar, S	1
Båvenholm, P; Brismar, K; de Faire, U; Eféndic, S; Ericsson, CG; Hamsten, A; Nilsson, J; Ruotolo, G	1
Vita, JA; Winniford, M; Yeung, AC	1
Hirano, T; Kazumi, T; Yoshino, G	1
Behar, S; Benderly, M; Boyko, V; Brunner, D; Goldbourt, U; Graff, E; Mandelzweig, L; Reicher-Reiss, H; Shotan, A; Tanne, D	1
Behar, S; Boyko, V; Goldbourt, U; Haim, M; Leor, J; Mekori, YA; Reshef, T; Tanne, D	1
Kudlacek, P; Sinzinger, H; Virgolini, I	1

Reviews

7 review(s) available for bezafibrate and Myocardial Infarction

Article	Year
Fibrates for secondary prevention of cardiovascular disease and stroke. The Cochrane database of systematic reviews, 2015, Oct-25, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke	2015
Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11 Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke	2016
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular diabetology, 2005, Sep-16, Volume: 4 Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Triglycerides	2005
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs, 1996, Volume: 52, Issue:5 Topics: Angina Pectoris; Apolipoproteins; Apolipoproteins A; Bezafibrate; Diabetes Complications; Drug Tolerance; Fibrinogen; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Myocardial Infarction	1996
Serum triglycerides and clinical benefit in lipid-lowering trials. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides	1998
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. European heart journal, 1998, Volume: 19 Suppl H Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides	1998
[BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Triglycerides	2001

Trials

22 trial(s) available for bezafibrate and Myocardial Infarction

Article	Year
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). The American journal of cardiology, 2009, Jan-01, Volume: 103, Issue:1 Topics: Aged; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Israel; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Survival Rate; Time Factors	2009
Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Archives of internal medicine, 2009, Mar-09, Volume: 169, Issue:5 Topics: Aged; Bezafibrate; Cholesterol, HDL; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Time Factors; Treatment Outcome	2009
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). The American journal of cardiology, 2010, Dec-15, Volume: 106, Issue:12 Topics: Aged; Bezafibrate; Blood Glucose; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperuricemia; Hypolipidemic Agents; Incidence; Israel; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Triglycerides; Uric Acid	2010
High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. American heart journal, 2004, Volume: 147, Issue:2 Topics: Aged; Bezafibrate; Blood Glucose; Coronary Disease; Diabetes Complications; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Proportional Hazards Models	2004
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation, 2004, May-11, Volume: 109, Issue:18 Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2004
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Archives of internal medicine, 2005, May-23, Volume: 165, Issue:10 Topics: Adult; Aged; Bezafibrate; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome	2005
Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). The American journal of cardiology, 2006, Feb-15, Volume: 97, Issue:4 Topics: Aged; Bezafibrate; Cholesterol, HDL; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Triglycerides	2006
Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease. Cardiology, 2007, Volume: 107, Issue:1 Topics: Bezafibrate; Case-Control Studies; Coronary Disease; Death, Sudden, Cardiac; Female; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors	2007
C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease. American heart journal, 2007, Volume: 154, Issue:6 Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Recurrence; Risk Factors	2007
Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. Journal of the American College of Cardiology, 2008, Jan-29, Volume: 51, Issue:4 Topics: Aged; Bezafibrate; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2008
Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Drugs under experimental and clinical research, 1995, Volume: 21, Issue:3 Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Myocardial Infarction; Patient Compliance; Research Design; Risk Factors; Triglycerides	1995
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. Journal of clinical epidemiology, 1995, Volume: 48, Issue:6 Topics: Age Factors; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Fibrinogen; Humans; Hypertension; Israel; Male; Middle Aged; Motor Activity; Multivariate Analysis; Myocardial Infarction; Risk Factors; Sex Factors; Smoking; Triglycerides	1995
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). The American journal of cardiology, 1993, Apr-15, Volume: 71, Issue:11 Topics: Aged; Algorithms; Bezafibrate; Cholesterol, HDL; Clinical Protocols; Coronary Artery Disease; Death, Sudden, Cardiac; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides	1993
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet (London, England), 1996, Mar-30, Volume: 347, Issue:9005 Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Feasibility Studies; Fibrinogen; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Risk Factors; Time Factors; Triglycerides	1996
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. The American journal of cardiology, 1996, Jun-15, Volume: 77, Issue:15 Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Aged; Bezafibrate; Case-Control Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Time Factors	1996
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism: clinical and experimental, 1998, Volume: 47, Issue:1 Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha	1998
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. European heart journal, 1998, Volume: 19 Suppl H Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides	1998
Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. European heart journal, 1998, Volume: 19 Suppl H Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Triglycerides	1998
Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1999, Volume: 10 Suppl 1 Topics: Aged; Bezafibrate; Coronary Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	1999
Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. Journal of the American College of Cardiology, 2000, Mar-01, Volume: 35, Issue:3 Topics: Adult; Bezafibrate; Biomarkers; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Lipoproteins; Male; Myocardial Infarction; Treatment Outcome	2000
A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. The American journal of medicine, 2001, Oct-15, Volume: 111, Issue:6 Topics: Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk; Severity of Illness Index; Stroke; Triglycerides	2001
[Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study]. Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:13 Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type V; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Triglycerides	1991

Other Studies

10 other study(ies) available for bezafibrate and Myocardial Infarction

Article	Year
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment. Cardiovascular diabetology, 2009, Jan-28, Volume: 8 Topics: Aged; Bezafibrate; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Randomized Controlled Trials as Topic; Severity of Illness Index	2009
Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis. Cardiology, 2003, Volume: 100, Issue:4 Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Bezafibrate; Cause of Death; Clinical Trials as Topic; Comorbidity; Coronary Disease; Cross-Sectional Studies; Female; Follow-Up Studies; Heart Failure; Humans; Israel; Male; Mathematical Computing; Middle Aged; Myocardial Infarction; Patient Selection; Risk Factors	2003
Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study. Archives of internal medicine, 2004, Feb-23, Volume: 164, Issue:4 Topics: Bezafibrate; Coronary Disease; Female; Humans; Hypolipidemic Agents; Leukocyte Count; Male; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Risk Factors	2004
The other side of the bezafibrate infarction prevention trial data. Archives of internal medicine, 2005, Nov-14, Volume: 165, Issue:20 Topics: Bezafibrate; Comorbidity; Humans; Hypolipidemic Agents; Incidence; Metabolic Syndrome; Myocardial Infarction; Preventive Medicine; Risk Factors	2005
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke, 2006, Volume: 37, Issue:7 Topics: Aged; Angina Pectoris; Bezafibrate; Brain Ischemia; C-Reactive Protein; Cerebral Infarction; Female; Fibrinogen; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Israel; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment	2006
Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity. Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:4 Topics: Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Middle Aged; Myocardial Infarction; Obesity; Time Factors; Triglycerides	2006
Low total cholesterol and high total mortality in patients with coronary heart disease. European heart journal, 1997, Volume: 18, Issue:8 Topics: Bezafibrate; Coronary Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Patient Selection; Survival Analysis	1997
Coronary artery reactivity after treatment with simvastatin. Current atherosclerosis reports, 2001, Volume: 3, Issue:2 Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome	2001
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire international, 1999, Volume: 8, Issue:42 Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome	1999
Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. Journal of the American College of Cardiology, 2002, Apr-03, Volume: 39, Issue:7 Topics: Bezafibrate; Case-Control Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Time Factors	2002